Management of Hepatitis C Viral Infection Pre- and Post-liver Transplantation.
10.4285/jkstn.2013.27.1.1
- Author:
Sung Won LEE
1
;
Si Hyun BAE
Author Information
1. Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. baesh@catholic.ac.kr
- Publication Type:Review
- Keywords:
Liver transplantation;
Hepatitis C;
Antiviral agents
- MeSH:
Antiviral Agents;
Hepatitis;
Hepatitis C;
Liver;
Liver Transplantation;
Recurrence;
Ribavirin;
Transplants
- From:The Journal of the Korean Society for Transplantation
2013;27(1):1-5
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
One of the strategies to improve the outcomes of liver transplantation of hepatitis C viral infection related diseases is antiviral therapy pre- and post-liver transplantation. The antiviral therapies have been attempted at various time points; pretransplantation period, pre-emptively after transplantation, a few months after transplantation, and in the cases of obvious recurrence. The goal of the pretransplantation antiviral therapy is to prevent HCV reinfection and the purpose of the posttransplantation antiviral therapy is to prevent HCV recurrence and liver damage. Peginterferon and ribavirin is the treatment of choice at this time but there are many treatment related side effects and the virologic response is still far from satisfactory. In this article, we have reviewed the results of the antiviral therapies against hepatitis C viral infection before and after liver transplantation and looked at the antiviral agents currently under investigation with special focus on the direct acting agents.
